EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion

Mayu Uemura, Anna Fong Na Goh, Amit Kumar, Gary Quagliotto, Pranav Dorwal iD

Genes, Chromosomes and Cancer · 2026-07 · 65 (7)

DOI: 10.1002/gcc.70153 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, online erschienen am 02.07.2026. Verfasst von Mayu Uemura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Monash Health, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Sarcoma, PAX3 Transcription Factor, Oncogene Proteins, Fusion, Trans-Activators. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biphenotypic sinonasal sarcoma (BSNS) is a rare, low‐grade spindle cell sarcoma of the sinonasal tract. It is characterized by dual neural and myogenic differentiation and classically shows fusions involving PAX3 . MAML3 , a co‐activator in the Notch signaling pathway, is the most common fusion partner of PAX3 . Here, we describe the first reported case, to our knowledge, of BSNS harboring a novel PAX3::MAML2 fusion in a polypoid lesion arising from the left ethmoid of a 61‐year‐old man. Microscopically, the tumor demonstrated bland spindle cell morphology. The cells were arranged in small fascicles and a vaguely whorled pattern without mitotic activity or cellular atypia. Immunohistochemistry displayed characteristic co‐expression of S100 and smooth muscle actin as well as patchy nuclear positivity for beta‐catenin. SOX10, AE1/AE3, EMA, and CD34 were negative. Ki‐67 was expressed in less than 1% of tumor cells, consistent with a low‐grade lesion. The RNA sequencing identified a novel PAX3::MAML2 fusion transcript. MAML2 fusion is commonly associated with other head and neck neoplasms, including mucoepidermoid carcinoma and NR1D1 ‐rearranged tumors. These findings highlight the value of comprehensive fusion testing in BSNS and emphasize the evolving fusion landscape in this entity and related tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaPAX3 Transcription FactorOncogene Proteins, FusionTrans-ActivatorsParanasal Sinus NeoplasmsTranscription FactorsHumansMaleMiddle Aged

Stichwörter der Autor:innen

RNARNA sequencecancer researchgene expression processnotch signaling pathwaypathologyspindle cell sarcoma

Substanzen

MAML2 protein, humanPAX3 Transcription FactorOncogene Proteins, FusionPAX3 protein, humanTrans-ActivatorsTranscription Factors

Autor:innen und Institutionen

  • Department of Pathology, Monash Health, Clayton, Victoria, Australia.
  • Sullivan Nicolaides Pathology, Bowen Hills, QLD, Australia.
  • School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Pranav Dorwal

Zitieren

APA

Uemura, M., Goh, A. F. N., Kumar, A., Quagliotto, G., & Dorwal, P. (2026). Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion. Genes, Chromosomes and Cancer, 65(7). https://doi.org/10.1002/gcc.70153

Vancouver

Uemura M, Goh AFN, Kumar A, Quagliotto G, Dorwal P. Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion. Genes, Chromosomes and Cancer. 2026;65(7). doi:10.1002/gcc.70153

BibTeX
@article{Uemura2026,
  author = {Uemura, Mayu and Goh, Anna Fong Na and Kumar, Amit and Quagliotto, Gary and Dorwal, Pranav},
  title = {Biphenotypic Sinonasal Sarcoma With a Novel PAX3::MAML2 Fusion},
  journal = {Genes, Chromosomes and Cancer},
  year = {2026},
  volume = {65},
  number = {7},
  doi = {10.1002/gcc.70153}
}
Kostenlos starten →